Gilead Sciences (GILD) Change in Receivables (2009 - 2026)

Gilead Sciences (GILD) has reported Change in Receivables for 18 consecutive years, with -$134.0 million the latest figure, recorded in Q1 2026.

• Change in Receivables for Q1 2026 came in at -$134.0 million, down 69.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $312.0 million (up 209.86% YoY), and the FY2025 annual result was $367.0 million, up 364.03% from the prior year.
• Change in Receivables was -$134.0 million for Q1 2026 at Gilead Sciences, up from -$179.0 million in the prior quarter.
• Over five years, Change in Receivables peaked at $612.0 million in Q3 2023 and troughed at -$699.0 million in Q1 2022.
• Average Change in Receivables over 5 years is $20.2 million, with a median of $29.0 million recorded in 2024.
• The widest YoY moves for Change in Receivables: up 906.9% in 2025, down 219.7% in 2025.
• Over 5 years, Change in Receivables stood at $281.0 million in 2022, then tumbled by 178.29% to -$220.0 million in 2023, then surged by 67.27% to -$72.0 million in 2024, then tumbled by 148.61% to -$179.0 million in 2025, then climbed by 25.14% to -$134.0 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were -$134.0 million in Q1 2026, -$179.0 million in Q4 2025, and $333.0 million in Q3 2025.